Abstract 481P
Background
Gastric cancer (GC) is the 4th most common malignancy worldwide and is 2nd leading cause of cancer-related deaths. Bone metastasis (BM) from GC occurs only rarely. The reported frequency of bone metastasis in GC patients is 13.4% to 15.9% in autopsy series and increases up to 45.3% in bone metastasis screening studies, whereas it has been reported in only 0.9% to 10% of patients in clinical practice. Purpose of study was to evaluate the incidence, clinicopathological characteristics, treatment outcomes, prognostic factors, and survival of GC patients with bone metastases.
Methods
Of 6345 GC patients who were treated between Jan 1995 and Dec 2022,186 patients were found to have BM. The treatment modalities included surgery (curative/palliative), radiotherapy and chemotherapy(adjuvant/palliative) and bisphosphonates administration. Descriptive statistics were expressed as the mean±standard deviation or median for continuous variables in conjunction with the number of subjects and percentage for categorical variables. The Pearson chi-square test and Student t-test were used to analyze frequencies and means respectively to compare the clinicopathological parameters was used to determine cumulative survival curves.
Results
A total of 6345 patients with GC were analyzed and BM was observed in 2.9% of the patients (n=186). The median interval from the diagnosis of GC to skeletal metastasis was 16months. The 3year OS rates were 26%, 14%, and 2% for patients with stage II, III, and IV GC respectively (Plog-rank＜0.001). The median OS and OS-BM were 16 and 6 months respectively. The median follow-up time after bone metastasis was 42.3 months. No significant differences were found in OS and OS-BM between patients with solitary and multiple BM. The median OS-BM was also similar between the patients with synchronous and metachronous bone metastases.
Conclusions
Bone metastasis of GC is often in multiple locations, metachronous, coexisting with visceral metastasis, and most commonly in the lumbar-thoracic vertebrae and pelvis. Early diagnosis and treatment are crucial to prevent the development of severe morbidity in GC patients with bone metastasis.
Clinical trial identification
CH-124.
Legal entity responsible for the study
CMCH Bhopal.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.